Research ExplorerPublicationsHaploidentical hematopoietic cell transplantation using in v...

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation

Standard

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. / Haen, Sebastian P; Groh, Christiane; Schumm, Michael; Backert, Linus; Löffler, Markus W; Federmann, Birgit; Faul, Christoph; Dörfel, Daniela; Vogel, Wichard; Handgretinger, Rupert; Kanz, Lothar; Bethge, Wolfgang A.

In: ANN HEMATOL, Vol. 96, No. 5, 05.2017, p. 817-827.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Haen, SP, Groh, C, Schumm, M, Backert, L, Löffler, MW, Federmann, B, Faul, C, Dörfel, D, Vogel, W, Handgretinger, R, Kanz, L & Bethge, WA 2017, 'Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation', ANN HEMATOL, vol. 96, no. 5, pp. 817-827. https://doi.org/10.1007/s00277-017-2941-x

APA

Haen, S. P., Groh, C., Schumm, M., Backert, L., Löffler, M. W., Federmann, B., Faul, C., Dörfel, D., Vogel, W., Handgretinger, R., Kanz, L., & Bethge, W. A. (2017). Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. ANN HEMATOL, 96(5), 817-827. https://doi.org/10.1007/s00277-017-2941-x

Vancouver

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B et al. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. ANN HEMATOL. 2017 May;96(5):817-827. https://doi.org/10.1007/s00277-017-2941-x

Bibtex

@article{ac870ec95d414e2c9c4018b698174935,
title = "Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation",
abstract = "Disease relapse after one or more allogeneic hematopoietic cell transplantations (HCT) represents a therapeutic challenge with all options bearing a significant morbidity and mortality. Haploidentical HCT may induce more pronounced anti-leukemic effects and was evaluated at our center in 25 consecutive patients with disease relapse after preceding HCT receiving haploidentical grafts after in vitro T cell depletion. Overall survival at 1 and 2 years was 32 and 14%, respectively. Of note, patients with complete remission (CR) before haploidentical HCT had a very favorable overall survival of 41.7% at 2 years. Cumulative incidence of non-relapse mortality was 36 and 40% at 1 and 2 years, respectively. With a cumulative incidence for relapse of 36 and 45.6% at 1 and 2 years, disease-free survival (DFS) was 28 and 14.4%, respectively. Here also, patients with CR before haploidentical HCT had a favorable DFS of 42% at 2 years. Only very limited acute (11 patients (44%) with a median grade 1) and chronic graft versus host disease (GvHD) (5 patients (11%), limited grade only) was observed. The main complications and causes of death comprised-besides relapse-infections and bleeding complications. Hence, haploidentical HCT can achieve long-term survival comparable to second transplantation with matched or mismatched donors for patients with otherwise deleterious prognosis and should be considered as a treatment option for patients experiencing disease relapse after previous allogeneic HCT.",
keywords = "Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Combined Modality Therapy, Female, Graft Survival, Graft vs Host Disease/etiology, Haplotypes, Hematopoietic Stem Cell Transplantation/adverse effects, Hematopoietic Stem Cells/immunology, Humans, Kaplan-Meier Estimate, Leukemia/complications, Lymphocyte Depletion, Male, Middle Aged, Mortality, Recurrence, Retreatment, Salvage Therapy, T-Lymphocytes, Tissue Donors, Transplantation Chimera, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult",
author = "Haen, {Sebastian P} and Christiane Groh and Michael Schumm and Linus Backert and L{\"o}ffler, {Markus W} and Birgit Federmann and Christoph Faul and Daniela D{\"o}rfel and Wichard Vogel and Rupert Handgretinger and Lothar Kanz and Bethge, {Wolfgang A}",
year = "2017",
month = may,
doi = "10.1007/s00277-017-2941-x",
language = "English",
volume = "96",
pages = "817--827",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation

AU - Haen, Sebastian P

AU - Groh, Christiane

AU - Schumm, Michael

AU - Backert, Linus

AU - Löffler, Markus W

AU - Federmann, Birgit

AU - Faul, Christoph

AU - Dörfel, Daniela

AU - Vogel, Wichard

AU - Handgretinger, Rupert

AU - Kanz, Lothar

AU - Bethge, Wolfgang A

PY - 2017/5

Y1 - 2017/5

N2 - Disease relapse after one or more allogeneic hematopoietic cell transplantations (HCT) represents a therapeutic challenge with all options bearing a significant morbidity and mortality. Haploidentical HCT may induce more pronounced anti-leukemic effects and was evaluated at our center in 25 consecutive patients with disease relapse after preceding HCT receiving haploidentical grafts after in vitro T cell depletion. Overall survival at 1 and 2 years was 32 and 14%, respectively. Of note, patients with complete remission (CR) before haploidentical HCT had a very favorable overall survival of 41.7% at 2 years. Cumulative incidence of non-relapse mortality was 36 and 40% at 1 and 2 years, respectively. With a cumulative incidence for relapse of 36 and 45.6% at 1 and 2 years, disease-free survival (DFS) was 28 and 14.4%, respectively. Here also, patients with CR before haploidentical HCT had a favorable DFS of 42% at 2 years. Only very limited acute (11 patients (44%) with a median grade 1) and chronic graft versus host disease (GvHD) (5 patients (11%), limited grade only) was observed. The main complications and causes of death comprised-besides relapse-infections and bleeding complications. Hence, haploidentical HCT can achieve long-term survival comparable to second transplantation with matched or mismatched donors for patients with otherwise deleterious prognosis and should be considered as a treatment option for patients experiencing disease relapse after previous allogeneic HCT.

AB - Disease relapse after one or more allogeneic hematopoietic cell transplantations (HCT) represents a therapeutic challenge with all options bearing a significant morbidity and mortality. Haploidentical HCT may induce more pronounced anti-leukemic effects and was evaluated at our center in 25 consecutive patients with disease relapse after preceding HCT receiving haploidentical grafts after in vitro T cell depletion. Overall survival at 1 and 2 years was 32 and 14%, respectively. Of note, patients with complete remission (CR) before haploidentical HCT had a very favorable overall survival of 41.7% at 2 years. Cumulative incidence of non-relapse mortality was 36 and 40% at 1 and 2 years, respectively. With a cumulative incidence for relapse of 36 and 45.6% at 1 and 2 years, disease-free survival (DFS) was 28 and 14.4%, respectively. Here also, patients with CR before haploidentical HCT had a favorable DFS of 42% at 2 years. Only very limited acute (11 patients (44%) with a median grade 1) and chronic graft versus host disease (GvHD) (5 patients (11%), limited grade only) was observed. The main complications and causes of death comprised-besides relapse-infections and bleeding complications. Hence, haploidentical HCT can achieve long-term survival comparable to second transplantation with matched or mismatched donors for patients with otherwise deleterious prognosis and should be considered as a treatment option for patients experiencing disease relapse after previous allogeneic HCT.

KW - Adolescent

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Combined Modality Therapy

KW - Female

KW - Graft Survival

KW - Graft vs Host Disease/etiology

KW - Haplotypes

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Hematopoietic Stem Cells/immunology

KW - Humans

KW - Kaplan-Meier Estimate

KW - Leukemia/complications

KW - Lymphocyte Depletion

KW - Male

KW - Middle Aged

KW - Mortality

KW - Recurrence

KW - Retreatment

KW - Salvage Therapy

KW - T-Lymphocytes

KW - Tissue Donors

KW - Transplantation Chimera

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1007/s00277-017-2941-x

DO - 10.1007/s00277-017-2941-x

M3 - SCORING: Journal article

C2 - 28247058

VL - 96

SP - 817

EP - 827

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 5

ER -